Eyeing functional cure, Excision raises $60M to advance CRISPR-based HIV program into Phase I/II 

With primate data in hand for its CRISPR-based HIV therapy, Excision raised a $60 million round to advance into the clinic this year. 

Antiretroviral therapy (ART) has succeeded in controlling HIV infection by blocking replication, but curing the infection has been challenging because latent provirus lurks in host chromosomes. Excision BioTherapeutics Inc. uses gene editing to cut out integrated latent viruses from host genomes. ...